Tramadol Hydrochloride: US FDA label indications
US FDA labelNot medical advice
Label details
- Brand name
- Tramadol Hydrochloride
- Generic name
- Tramadol Hydrochloride
- Manufacturer
- Proficient Rx LP
- Route
- Oral
- Product type
- Human Prescription Drug
- Substance
- Tramadol Hydrochloride
- Application number
- ANDA201384
Indications and usage (label excerpt)
INDICATIONS AND USAGE Tramadol hydrochloride extended-release tablets are indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.
Warnings (label excerpt)
WARNINGS Seizure Risk Seizures have been reported in patients receiving tramadol within the recommended dosage range. Spontaneous postmarketing reports indicate that seizure risk is increased with doses of tramadol above the recommended range. Concomitant use of tramadol increases the seizure risk in patients taking: • Selective serotonin re-uptake inhibitors (SSRI antidepressants or anorectics), • Tricyclic antidepressants (TCAs), and other tricyclic compounds (e.g., cyclobenzaprine, promethazine, etc.), or • Other opioids. Administration of tramadol may enhance the seizure risk in patients taking: • MAO inhibitors (see also WARNINGS - Use with MAO Inhibitors ), • Neuroleptics, or • Other drugs that reduce the seizure threshold. Risk of convulsions may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (such as head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections). In tramadol overdose, …
Excerpts are shortened. Read the full label, and ask a pharmacist or prescriber about any medicine. Full label on DailyMed(opens in a new tab) For products sold in Canada, see the Health Canada Drug Product Database(opens in a new tab).
Trials whose interventions mention this drug
Canadian trials first. A match on the drug name does not mean the trial studied this specific product.
5 trials, recruiting first
| Phase | Countries | ||||
|---|---|---|---|---|---|
| Efficacy and Safety of Canadá Association in the Treatment of Chronic Pain NCT05125978 | Withdrawn | Phase 2 | EMS | 2026-09 | |
| Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain NCT04589494 | Unknown status | Phase 2, Phase 3 | Egypt | Assiut University | 2020-04-16 |
| An Efficacy and Safety Study of Acetaminophen Plus Tramadol Hydrochloride (JNS013) in Participants With Chronic Pain NCT00736853 | Completed | Phase 3 | Japan | Janssen Pharmaceutical K.K. | 2008-06 |
| A Long-term Efficacy and Safety Study of Tramadol Hydrochloride Plus Acetaminophen (JNS013) in Japanese Participants With Chronic Pain NCT00736957 | Completed | Phase 3 | Japan | Janssen Pharmaceutical K.K. | 2008-05 |
| Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain. NCT00290901 | Completed | Phase 4 | Puerto Rico, United States | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2006-03 |
Source: openFDA drug label (US FDA), snapshot October 2026. Not a Health Canada Product Monograph.